Indications & formulation #
ADHD in adults. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral capsule · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Start 40 mg/day; after at least three days, target 80 mg/day. If needed after 2–4 additional weeks, maximum 100 mg/day. CYP2D6 modifiers change titration.
Contraindications & important cautions #
Avoid MAOIs, phaeochromocytoma, narrow-angle glaucoma and severe cardiovascular disease. Assess hepatic symptoms and mood changes.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Appetite, gastrointestinal, sleep and cardiovascular effects require review; follow the selected label’s serious warnings.
Interactions #
CYP2D6 status/modifiers affect exposure. Review cardiovascular disease and contraindicated combinations.
Monitoring #
Monitor function, blood pressure/pulse, weight/appetite and mood-related changes, with age-specific requirements.
Special populations #
Moderate hepatic impairment: half usual dose; severe: one-quarter. Strong CYP2D6 inhibitors/poor metabolism need slower escalation.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
The label does not require tapering; reassess function and cardiovascular effects when treatment changes.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Atomoxetine
Adult ADHD
Adults · Capsule · Oral · US STRATTERA label, June 2026
- Starting dose
- 40 mg/day.
- Titration
- Increase to 80 mg/day after at least 3 days; consider 100 mg/day after another 2–4 weeks if response remains suboptimal.
- Treatment range / target
- Target 80 mg/day; maximum 100 mg/day, once daily or evenly divided morning/late afternoon.
- Maximum / limits
- 100 mg/day.
- Trial & duration
- Reassess long-term usefulness. Label permits discontinuation without tapering.
- Monitoring
- Pulse/BP, activation, urinary symptoms and possible hepatic injury.
- Population & organ-function adjustments
- Strong CYP2D6 inhibitor or poor metabolizer: wait 4 weeks before increasing. Child-Pugh B: use 50% of usual initial/target doses; C: 25%.
- Important cautions
- Screen for bipolar disorder. Contraindicated with MAOIs, narrow-angle glaucoma, pheochromocytoma and severe cardiovascular disorders. Swallow capsules whole.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Atomoxetine — Oral capsule — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral capsule · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- DailyMed: STRATTERA prescribing information, June 2026 · United States label · Checked 2026-10-26 · Supports: Atomoxetine — Adult ADHD (Capsule)